Advertisement

Fall 23: Spätschäden – 53 Jahre, ♂, DM Typ 1, früher Nikotinabusus, periphere arterielle Verschlusskrankheit

  • Lars Kihm
Chapter

Zusammenfassung

Ein 53-jähriger Patient mit Typ-1-Diabetes seit dem 20. Lebensjahr, Zustand nach Nikotinkonsum bis vor 15 Jahren, Neuropathie, Retinopathie und jetzt bei peripherer arterieller Verschlusskrankheit einer schmerzfreien Gehstrecke von 180 Metern. Was ist gesichert in der Therapie?

Literatur

  1. Action to Control Cardiovascular Risk in Diabetes Study G, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT (2008) Effects of intensive glucose lowering in type 2 diabetes. New Engl J Med 358(24):2545–2559.  https://doi.org/10.1056/NEJMoa0802743CrossRefGoogle Scholar
  2. ADVANCE Collaborative Group, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358(24):2560–2572.  https://doi.org/10.1056/NEJMoa0802987CrossRefGoogle Scholar
  3. Belch J, MacCuish A, Campbell I, Cobbe S, Taylor R, Prescott R, Lee R, Bancroft J, MacEwan S, Shepherd J, Macfarlane P, Morris A, Jung R, Kelly C, Connacher A, Peden N, Jamieson A, Matthews D, Leese G, McKnight J, O’Brien I, Semple C, Petrie J, Gordon D, Pringle S, MacWalter R, Prevention of Progression of Arterial D, Diabetes Study G, Diabetes Registry G, Royal College of Physicians E (2008) The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. Bmj 337:a1840.  https://doi.org/10.1136/bmj.a1840CrossRefGoogle Scholar
  4. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH, investigators C (2004) Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364(9435):685–696.  https://doi.org/10.1016/S0140-6736(04)16895-5CrossRefGoogle Scholar
  5. Diabetes C, Complications Trial Research G, Nathan DM, Genuth S, Lachin J, Cleary P, Crofford O, Davis M, Rand L, Siebert C (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New Engl J Med 329 (14): 977–986.  https://doi.org/10.1056/nejm199309303291401
  6. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O (2003) Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. New Engl J Med 348(5):383–393.  https://doi.org/10.1056/NEJMoa021778CrossRefPubMedGoogle Scholar
  7. Knopp RH, d’Emden M, Smilde JG, Pocock SJ (2006) Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes care 29(7):1478–1485.  https://doi.org/10.2337/dc05-2415CrossRefPubMedGoogle Scholar
  8. Soejima H, Morimoto T, Saito Y, Ogawa H (2010) Aspirin for the primary prevention of cardiovascular events in patients with peripheral artery disease or diabetes mellitus. Analyses from the JPAD, POPADAD and AAA trials. Thromb haemost 104(6):1085–1088.  https://doi.org/10.1160/TH10-05-0333CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature 2018

Authors and Affiliations

  1. 1.Abteilung Innere Medizin IMedizinische UniversitätsklinikHeidelbergDeutschland

Personalised recommendations